Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
- Astellas, Osaka University Join Hands in Cell Therapy Research
February 3, 2015
- Sumitomo Dainippon Revving Up “Post-Latuda” Development Drive
February 3, 2015
- 2014 Was “Difficult Year” as Generics Gained Ground: Kyowa Kirin Pres.
February 3, 2015
- Takeda Terminates Development of Combined Quadruple Vaccine
February 3, 2015
- Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015
- Drug Price Cuts, Generic Erosion Weigh Kyowa Kirin Earnings
February 2, 2015
- Over 500 Daiichi Sankyo Employees Take Voluntary Redundancy
February 2, 2015
- Astellas Licenses Pollinosis Vaccine from Immunomic Therapeutics
February 2, 2015
- Kyowa Hakko Bio Names Mr Kotani as New President
February 2, 2015
- Chugai to Set Up Global Organization to Bolster Early Clinical Development Functions
January 30, 2015
- Abilify Rakes in US Sales of Nearly US$5 Billion in 2014: Otsuka
January 29, 2015
- Chugai Sales Grow 8.8% Thanks to Increasing Actemra Exports
January 29, 2015
- Astellas, Takeda to Lead Pack in FY2018 Japan Pharma Market: Citi Analyst
January 29, 2015
- Otsuka Establishes Marketing Base in Australia
January 29, 2015
- Astellas to Transfer Marketing Rights for 3 APIs to OrphanPacific
January 28, 2015
- PD-1, PD-L1 Inhibitors Could Carve Out 750 Billion Yen Market in Japan: Citi Analyst
January 28, 2015
- Takeda Launches Fomepizole
January 28, 2015
- Galderma Terminates Comarketing Agreement with Sato Pharmaceutical for Pekiron Cream
January 28, 2015
- Torii Files NDA for Sublingual Tablet for Mite Allergic Rhinitis
January 28, 2015
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…